Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Multiple Myeloma
About this trial
This is an interventional treatment trial for Multiple Myeloma focused on measuring Multiple Myeloma, Thalidomide, dose, dexamethasone
Eligibility Criteria
Inclusion Criteria:
- Patient over 18 years who has been informed about the potential risks and side effects of the treatment and having signed an informed consent to take part in the various aspects of the study.
- Having a refractory or relapsed multiple myeloma after at least two courses of treatment.
- The patients with a refractory or relapsed multiple myeloma after a single course of treatment that included an alkylating drug, can be included if there is no alternative treatment.
Concerning the thalidomide: Agreement to use and introduction of effective contraception by all the patients:
For women of childbearing potential
- Oral estroprogestogen contraception introduced at least 1 month before the first administration of thalidomide, and continued until the first menstruation following the end of the treatment, and their partners use a condom.
- Qualitative serum test for beta-HCG negative: to be done on Day 2 or 3 of the menstrual cycle just before the 1st prescription of thalidomide; in a context of spaniomenorrhea or amenorrhea the test should be done within 3 days after the 1st prescription of thalidomide.
For post-menopausal women
1st situation: Known sterility due to:
- total hysterectomy;
- total ovariectomy;
- total salpingectomy
2nd situation: Natural menopause
- amenorrhea for at least 1 year and
- negative progestagen test and
- plasma FSH > 50 IU/l
- For men: Throughout the duration of the treatment and for 3 months after the end of the protocol (i.e. one spermatogenesis cycle), sexual intercourse must always be protected by using a condom.
Exclusion Criteria:
- Pregnant or breast-feeding women or those of childbearing potential who are not using an effective method of contraception or the lack of protection during sexual intercourse in men.
- Patients who have already received treatment with thalidomide.
- Contraindication to thalidomide.
- Patient who has an absolute contraindication to dexamethasone.
- Patient with a history of deep vein thrombosis and who is not taking effective oral anticoagulation (the anticoagulant must be continued throughout the entire study).
- Performance index more than or equal to 3, unless the patient is bedridden as a result of the progress of the myeloma.
- Any situations that do not permit adequate follow-up of the study.
Sites / Locations
- Hopital St Joseph
- UCL de Mont Godine
- Chu D'Angers - Medecine D
- Centre Hospitalier D'Annecy - Service d'oncohématologie
- Centre Hospitalier H. Duffaut - Hematologie
- HOPITAL JEAN MINJOZ - Médecine interne/Hématologie
- Centre Hospitalier de Blois - Unité d'Onco-Hématologie
- Hopital Avicenne - Medecine Interne/Hematologie
- Centre Hospitalier Du Dr Duschene - Hematologie
- Hopital Morvan - Service Hematologie
- Polyclinique Du Parc - Hematologie
- Centre François Baclesse
- Centre Hospitalier - Service Hematologie
- H.I.A. Percy Hematologie
- Centre Hospitalier General - Medecine Interne
- Hopital Albert Michallon - Hematologie
- CENTRE HOSPITALIER DEPARTEMENTAL - Sce Médecine A
- Centre Hospitalier La Rochelle - Unité d'Oncologie Médicale
- Centre Hospitalier - Service de Médecine 7
- Clinique Victor Hugo
- CHRU CLAUDE HURIEZ - Maladies du sang
- Chu Edouard Herriot
- INSTITUT PAOLI CALMETTE - Unité transplantation
- CHR Hôp N.D. de Bon Secours - Service de Médecine A
- Hopital Jacques Monod - Rhumatologie
- CHRU Hôtel Dieu, Service des Maladies du Sang
- Centre Lacassagne
- Institut Curie - Service d'hématologie
- HOPITAL ST ANTOINE - Maladies du Sang
- Centre Hospitalier Général - Service d'Hématologie
- Hopital Du Haut Leveque - Hematologie
- Centre Hospitalier de Lyon Sud
- CHRU Jean Bernard - Hématologie
- Centre Hospitalier Laennec - Service de Médecine A
- Hôpital Robert Debré - Hématologie
- C.H.R. de Pontchaillou - Hématologie
- CHRU Hôpital Sud - Médecine Interne
- Centre Henri Becquerel - Service Hématologie
- C.H.U. de Saint Etienne - Hôpital Bellevue - Sce Rhumatologie
- Hôpital Nord - Hématologie
- CHU Hautepierre - Service Hématologie
- HOPITAL HAUTEPIERRE - Service Rhumatologie
- C.H.U. Rangueil - Service Rhumatologie
- C.H.U. PURPAN - Service Hématologie
- C.H.U. Bretonneau
- Centre Hospitalier - Service de Rhumatologie
- Centre Hospitalier - Hématologie
- CHU Hôpital Brabois - Médecine interne-Hématologie
- Centre Hospitalier Chubert - Médecine Interne
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
A
B
Thalidomide 100mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression
Thalidomide 400mg/day. Dexamethasone is administered at a dose of 40 mg/d, on 4 consecutive days (D1 - D4), with one course every four week in case of stable disease after 12 weeks of treatment or in case of Disease Progression